EP Patent

EP1287133A2 — Regulation of human dopamine-like g protein-coupled receptor

Assigned to Bayer AG · Expires 2003-03-05 · 23y expired

What this patent protects

Reagents which regulate human dopamine-like G protein-coupled receptor (DA-like GPCR) and reagents which bind to human DA-like GPCR gene products can play a role in preventing, ameliorating, or correcting dysfunctions or diseases including, but not limited to, obesity and disease…

USPTO Abstract

Reagents which regulate human dopamine-like G protein-coupled receptor (DA-like GPCR) and reagents which bind to human DA-like GPCR gene products can play a role in preventing, ameliorating, or correcting dysfunctions or diseases including, but not limited to, obesity and diseases related to obesity, cancer, diabetes, osteoporosis, anxiety, depression, hypertension, migraine, compulsive disorders, schizophrenia, autism, neurodegenerative disorders, such as Alzheimer's disease, Parkinsonism, and Huntington's chorea, and cancer chemotherapy-induced vomiting.

Drugs covered by this patent

Patent Metadata

Patent number
EP1287133A2
Jurisdiction
EP
Classification
—
Expires
2003-03-05
Drug substance claim
No
Drug product claim
No
Assignee
Bayer AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.